Benzinga | Nov 15, 2021 11:03AM EST

Portage Biotech Highlights Efficacy And Survival Data Presented On Intensity Therapeutics' INT230-6 (PORT-1) At November Scientific Conferences

Data presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Connective Tissue Oncology Society (CTOS) Annual Meeting suggest INT230-6 (PORT-1) offers a promising approach to treating metastatic disease, including advanced soft tissue sarcomas Data from Intensity Therapeutics' Phase 2 IT-01 clinical trial show that INT230-6 (PORT-1) is safe when administered both as a monotherapy and in combination with checkpoint inhibitors